FIELD: medicine.
SUBSTANCE: group of inventions relates to methods of treating aHUS in an adult human patient aged 18 years or older using an anti-C5 antibody. Anti-C5 antibody is an antibody containing a heavy chain polypeptide with SEQ ID NO: 14, light chain polypeptide with SEQ ID NO: 11, or is ravulizumab. Anti-C5 antibody is administered in a specific dose amount based on the patient’s body weight and in accordance with a specific dose schedule.
EFFECT: inventions provide improved methods of treating patients with aHUS.
42 cl, 23 dwg, 22 tbl, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| HUMAN ANTIBODIES TO PCSK9 FOR USE IN METHODS OF TREATING SPECIFIC GROUPS OF INDIVIDUALS | 2012 |
|
RU2721279C2 |
| STABLE COMPOSITIONS OF ANTI-TIGIT ANTIBODIES, INDIVIDUALLY AND IN COMBINATION WITH ANTIBODIES AGAINST PROGRAMMED DEATH RECEPTOR 1 (PD-1), AND METHODS OF THEIR USE | 2018 |
|
RU2820576C2 |
| ANTIBODY AGAINST B7-H3, ITS ANTIGEN-BINDING FRAGMENT AND THEIR MEDICAL USE | 2018 |
|
RU2765306C2 |
| TETANUS TOXIN ANTIBODY AND USE THEREOF | 2020 |
|
RU2815280C1 |
| ANTIBODIES AGAINST TISSUE FACTOR PATHWAY INHIBITOR AND THEIR USE | 2016 |
|
RU2815681C1 |
| ANTIBODY AGAINST BETA-AMYLOID, ANTIGEN-BINDING FRAGMENT OF SAID ANTIBODY, AND APPLICATION THEREOF | 2019 |
|
RU2777844C1 |
| PREDICTION OF RISK OF DEVELOPMENT OF UNDESIRED REACTION RELATED TO ADMINISTRATION OF ANTIBODY TO ALK2 AND CAPABILITY OF RESPONDING TO TREATMENT WITH ANTIBODY TO ALK2 | 2019 |
|
RU2783762C2 |
| BISPECIFIC ANTIGEN-BINDING MOLECULES CONTAINING ANTI-FAP CLONE 212 | 2019 |
|
RU2799429C2 |
| ANTIBODY AGAINST IL-5, ITS ANTIGEN-BINDING FRAGMENT AND ITS MEDICAL USE | 2018 |
|
RU2772716C2 |
| ANTIBODY BINDING HUMAN IL-4R, ANTIGEN-BINDING FRAGMENT THEREOF, AND MEDICAL APPLICATION THEREOF | 2019 |
|
RU2779649C1 |
